Skip to content

BioCryst Pharmaceuticals

US · BCRX #2766 by market cap Listed 1970
7.22 -0.10 -1.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 7.29 -0.41%
After-hours 7.10 -1.66%
11.117.227.222026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BCRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -11.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 10.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B

The radar needs all six factors. Available grades are shown below.

Valuation B+

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 12.2x Better than 67%
Price / Sales 2.0x Better than 57%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability B

How much profit the business keeps from each dollar of sales and capital.

Gross margin 97.8% Better than 99%
Operating margin 39.0% Better than 95%
Net margin 30.2% Better than 90%
Return on equity -1,925.4% Better than 0%
Return on invested capital -92.8% Better than 2%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -24.4% Better than 24%
6-month return -12.9% Better than 35%
12-month return (ex latest month) 11.6% Better than 48%
Distance below 52-week high 35.7% Better than 33%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.1x Better than 57%
Debt to assets 85.4% Better than 3%
Interest coverage 4.4x Better than 54%
Free cash flow / net income 130.7% Better than 57%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 66.7% Better than 41%
Upside to average target 135.5% Better than 89%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -5.12%
1M -9.07%
3M -25.26%
6M -17.39%
YTD -7.44%
1Y +2.70%
3Y +33.70%
5Y -39.28%

Key statistics

Price & volume

Prev close
7.32
Open
7.26
Day range
7.15 - 7.39
Avg price
7.25
Volume
3.85M
Turnover
27.91M
Amplitude
3.35%
52-week range
6.23 - 11.22

Valuation

P/E
5.97
P/E (TTM)
-5.64
P/B
-4.68
EPS
1.21
Net profit
311.33M
Net assets
-397.27M

Share structure

Market cap
1.86B
Float cap
1.73B
Shares out
257.30M
Float shares
239.51M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 20% of range
6.23 11.22

35.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-39.60M net over the window

Short interest

Shares short
27.64M
As of
2026-10-30

Frequently asked questions

What is the current stock price of BioCryst Pharmaceuticals (BCRX)?

BioCryst Pharmaceuticals last traded at 7.22. This page shows a periodic quote snapshot. Check the displayed quote time.

What is BioCryst Pharmaceuticals's market cap?

About 1.86B.

What is the P/E ratio of BioCryst Pharmaceuticals?

The trailing twelve-month P/E is -5.64. The Valuation tab shows it against the stock's own five-year range.

Does BioCryst Pharmaceuticals pay a dividend?

BioCryst Pharmaceuticals does not currently pay a regular dividend.

Is BioCryst Pharmaceuticals a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 17.00, which implies 135.5% upside from the current price. This is not investment advice.

What is BioCryst Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates BioCryst Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

BioCryst Pharmaceuticals discussion 0 comments

Add a comment